Details

Autor(en) / Beteiligte

• Pebody, Richard
• Warburton, Fiona
• Andrews, Nick
• Ellis, Joanna
• von Wissmann, Beatrix
• Robertson, Chris
• Yonova, Ivelina
• Cottrell, Simon
• Gallagher, Naomh
• Green, Helen
• Thompson, Catherine
• Galiano, Monica
• Marques, Diogo
• Gunson, Rory
• Reynolds, Arlene
• Moore, Catherine
• Mullett, David
• Pathirannehelage, Sameera
• Donati, Matthew
• Johnston, Jillian
• de Lusignan, Simon
• McMenamin, Jim
• Zambon, Maria

Titel

Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results

Ist Teil von

• Euro surveillance : bulletin européen sur les maladies transmissibles, 2015-09, Vol.20 (36), p.1

Ort / Verlag

Sweden: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Open access e-journals list

Beschreibungen/Notizen

• The 2014/15 influenza season in the United Kingdom (UK) was characterised by circulation of predominantly antigenically and genetically drifted influenza A(H3N2) and B viruses. A universal paediatric influenza vaccination programme using a quadrivalent live attenuated influenza vaccine (LAIV) has recently been introduced in the UK. This study aims to measure the end-of-season influenza vaccine effectiveness (VE), including for LAIV, using the test negative case-control design. The overall adjusted VE against all influenza was 34.3% (95% confidence interval (CI) 17.8 to 47.5); for A(H3N2) 29.3% (95% CI: 8.6 to 45.3) and for B 46.3% (95% CI: 13.9 to 66.5). For those aged under 18 years, influenza A(H3N2) LAIV VE was 35% (95% CI: -29.9 to 67.5), whereas for influenza B the LAIV VE was 100% (95% CI:17.0 to 100.0). Although the VE against influenza A(H3N2) infection was low, there was still evidence of significant protection, together with moderate, significant protection against drifted circulating influenza B viruses. LAIV provided non-significant positive protection against influenza A, with significant protection against B. Further work to assess the population impact of the vaccine programme across the UK is underway.